U.S. Tissue Diagnostics Market 2021 Global Analysis by Application, Type,
Vendor, Platform, Drivers and Key Players
The U.S. tissue diagnostics market size was valued at USD 2.07 billion in 2020 and is expected to
grow at a compound annual growth rate (CAGR) of 3.91% from 2021 to 2028. The market is
collectively driven by emerging solutions pertaining to digital tissue diagnostics, advancements in
imaging techniques & increasing affordability of diagnostics, and growth of personalized
therapeutics & diagnostics. The use of digital slides has significantly increased in recent years, owing
to its associated benefits including flexible magnification and remote access to slides.
Companies are supporting the development of precision medicine with novel oncology solutions. For
instance, in May 2020, QIAGEN launched new oncology solutions, such as the QCI Interpret One
software solution for genomic profiling of tumors. The advancements in imaging techniques are
expected to positively influence the market growth. According to Breastcancer.org, breast cancer is
the most common type of cancer diagnosed among American women. In 2021, it is estimated that
around 30% of the new cases of cancer in women would be breast cancers.
Key Player Mentioned:
Thermo Fisher Scientific, Inc.
F. Hoffmann-La Roche Ltd.
Siemens Healthineers AG
Becton, Dickinson & Company (BD)
Agilent Technologies, Inc.
General Electric Company (GE Healthcare)
To identify the key drivers and the competitors’ insights, Request a Sample @:
Product Segment Analysis:
Non-Small Cell Lung Cancer (NSCLC)
Regional Segment Analysis: North America, Europe, Asia Pacific, Latin America, and Mideast and
With technological improvements in imaging techniques, the sensitivity o